Epitomics

Burlingame, United States Founded: 2001 • Age: 25 yrs Listed Acquired By Abcam
Monoclonal antibody technology and products are developed by Epitomics.

About Epitomics

Epitomics is a Healthcare company based in Burlingame (United States) founded in 2001 by Weimin Zhu and Guo Liang Yu, and was acquired by Abcam in March 2012. Monoclonal antibody technology and products are developed by Epitomics. Epitomics has raised $16.21 million across 3 funding rounds from investors including Abcam, Sycamore Ventures and Amkey Ventures. Its chief executive, as recorded, is Guo Liang Yu. Epitomics offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is Abcam Limited. Its competitors include GenScript, Vector Laboratories and Allele Biotech; 2 of its 3 listed competitors have raised funding.

Company details

Epitomics is a biotechnology focussed on developing MAb technology and products. It developed rabbit MAb technology RabMAb for the creation of specific and custom rabbit MAbs that has potential in new MAb therapies. It claims that the MAbs produced from the technology acted as challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds and has benefitted more than 550 institutions and 150 pharma and biotech companies. In March 2012, Abcam acquired Epitomics and since then working as its subsidiary.

  • Headquarters Burlingame, United States
  • Founders Weimin Zhu, Guo Liang Yu
  • Stage Acquired
  • Sectors
    Healthcare
  • Website epitomics.com
  • Social LinkedIn YouTube
  • Acquired by Abcam (Mar 2012)
  • Legal Name Abcam Limited
Key Metrics
  • Total Equity Funding
    $16.21M (USD)

    in 3 rounds

  • Latest Funding Round
    $2.11M (USD), Series C

    Jan 2009

  • Investors
    Abcam

    & 3 more

  • Acquired by
    Abcam

    (Mar 2012)

Products & Services of Epitomics

Epitomics offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines.

Primary Antibodies
Research Tools

High-specificity antibodies for detecting proteins in experiments.

ELISA Kits
Assay Tools

Kits for sensitive immunoassay detection of various targets.

Cell Lines
Biological Materials

Validated cell lines for gene-editing and research applications.

Apps and channels of Epitomics

its YouTube channel Abcam has 2.43K subscribers and 30 videos.

Abcam
YouTube 2.43K subscribers 30 videos Science & Technology
Open channel

Videos from Epitomics

The most watched videos on Epitomics's YouTube channel, Abcam (2.43K subscribers). Click a video to play it here.

Guide to cancer biomarkers
16.4K views
A career-defining discovery | Dr. Gina R. Poe
12.8K views
Gene regulation with PRC2 and PRC1
11.2K views
Direct and indirect flow cytometry video protocol
8K views

More on Abcam.

Funding Insights of Epitomics

Epitomics has successfully raised a total of $16.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $2.11 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $16.21M
  • Total Rounds 3
  • Last Round Series C β€” $2.11M
  • First Round $3.1M

    (Mar 2003)

  • Investors Count 3

All 3 funding rounds of Epitomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2009$2.11MSeries C––
–
Apr 2004$11MSeries C––
Mar 2003$3.1MSeries B––
Valuation history

4 investors in total: 4 institutional.

Investors in Epitomics

Epitomics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Abcam, Sycamore Ventures and Amkey Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
sycaventures.com
amkeyvc.com
kensonventures.com
Biological reagents and antibodies are developed for life science research.
1998abcam.comCambridge, United Kingdom
Premium access

Investor details for Epitomics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Epitomics

2 people are tracked at Epitomics (2 in leadership).

NameRoleGroup
Weimin Zhu
Co-FounderLeadership
Guo Liang Yu
Co-Founder & CEOLeadership
Premium access

Complete people profiles for Epitomics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Epitomics

5 dated milestones of Epitomics across 11 years, from founding to its latest funding, stage changes and deals.

  1. Founded Epitomics is founded.
  2. Funding First funding round of $3.1M.
  3. Funding Latest funding round, Series C, of $2.1M.
  4. IPO Lists on the stock exchange (IPO).
  5. Exit Acquired by Abcam.

Competitors of Epitomics

Epitomics has 3 listed competitors in our database, 2 of them funded. They include GenScript, Vector Laboratories and Allele Biotech.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
genscript.com2002Piscataway, United States$15M5,260
Reagents and instruments are provided for life sciences research.
vectorlabs.com1976Burlingame, United States
Labeling and detection reagents immunohistochemistry studies and other life science research applications
allelebiotech.com1999San Diego, United States$18M
Nano-antibodies, iPSCs, fluorescent proteins, and RNAi are developed.
Premium access

Detailed competitors of Epitomics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Epitomics

Websites that share an audience with Epitomics (epitomics.com).

Similar websites

Websites whose visitors overlap most with Epitomics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
everestbiotech.com
100%
1.6K#10,518,665View details
abgent.com
92%
View details
bioworlde.com
90%
#4,508,617View details
fusionantibodies.com
89%
View details
abnova.com
88%
30.7K#957,320View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 24 similar websites and full traffic analytics for Epitomics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 24 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Epitomics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Epitomics

Premium access

Complete news archive for Epitomics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Epitomics

Epitomics was founded in 2001 and raised its 1st funding round 2 years after it was founded.

Epitomics is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.

Guo Liang Yu is the CEO of Epitomics, as recorded in our data. They have also founded this company.

Epitomics is a funded company, having raised a total of $16.21M across 3 funding rounds to date. The company's 1st funding round was a Series B of $3.1M, raised on Mar 2003.

Epitomics is a biotechnology focussed on developing MAb technology and products. It developed rabbit MAb technology RabMAb for the creation of specific and custom rabbit MAbs that has potential in new MAb therapies. It claims that the MAbs produced from the technology acted as challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds and has benefitted more than 550 institutions and 150 pharma and biotech companies. In March 2012, Abcam acquired Epitomics and since then working as its subsidiary.

Epitomics's top competitors include GenScript, Vector Laboratories and Allele Biotech.

Epitomics offers Primary Antibodies, ELISA Kits, and Cell Lines.

Epitomics has 4 investors. Key investors include Abcam, Sycamore Ventures, Amkey Ventures, and Kenson Ventures.

Epitomics operates through Abcam Limited.

Yes. Epitomics was acquired by Abcam in March 2012.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available